Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 - a sharp decline from the $2.8bn recorded in the ...

Moderna (MRNA) has been a classic example of how one successful product can propel a biotech stock to new heights in a matter of months. Before developing its COVID-19 vaccine, Moderna had no approved ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human ...

There are a lot of empty words at these types of proceedings, but those were not. The Spyteks are co-founders of the National ...

An epidemiologist said the Franklin County resolution was "based on conspiracy and misinformation against the COVID-19 ...